IL158384A0 - Treatment or prophylaxis of insulin producing cell graft rejection - Google Patents
Treatment or prophylaxis of insulin producing cell graft rejectionInfo
- Publication number
- IL158384A0 IL158384A0 IL15838402A IL15838402A IL158384A0 IL 158384 A0 IL158384 A0 IL 158384A0 IL 15838402 A IL15838402 A IL 15838402A IL 15838402 A IL15838402 A IL 15838402A IL 158384 A0 IL158384 A0 IL 158384A0
- Authority
- IL
- Israel
- Prior art keywords
- graft rejection
- producing cell
- prophylaxis
- cell graft
- treatment
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 4
- 102000004877 Insulin Human genes 0.000 title abstract 2
- 108090001061 Insulin Proteins 0.000 title abstract 2
- 206010052779 Transplant rejections Diseases 0.000 title abstract 2
- 229940125396 insulin Drugs 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 229940124073 Complement inhibitor Drugs 0.000 abstract 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 abstract 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000004074 complement inhibitor Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 150000002596 lactones Chemical class 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29706901P | 2001-06-08 | 2001-06-08 | |
| PCT/EP2002/006278 WO2002100148A2 (en) | 2001-06-08 | 2002-06-07 | Treatment or prophylaxis of insulin-producing cell graft rejection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL158384A0 true IL158384A0 (en) | 2004-05-12 |
Family
ID=23144725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15838402A IL158384A0 (en) | 2001-06-08 | 2002-06-07 | Treatment or prophylaxis of insulin producing cell graft rejection |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US20030003099A1 (enExample) |
| EP (1) | EP1429845B1 (enExample) |
| JP (1) | JP4476623B2 (enExample) |
| CN (1) | CN1524002A (enExample) |
| AT (1) | ATE424893T1 (enExample) |
| AU (1) | AU2002320828B2 (enExample) |
| BR (1) | BR0209319A (enExample) |
| CA (1) | CA2445605A1 (enExample) |
| DE (1) | DE60231522D1 (enExample) |
| ES (1) | ES2322442T3 (enExample) |
| IL (1) | IL158384A0 (enExample) |
| NO (1) | NO20035434D0 (enExample) |
| NZ (1) | NZ529044A (enExample) |
| PL (1) | PL364359A1 (enExample) |
| PT (1) | PT1429845E (enExample) |
| RU (1) | RU2003136730A (enExample) |
| WO (1) | WO2002100148A2 (enExample) |
| ZA (1) | ZA200307893B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60213766T2 (de) * | 2001-02-22 | 2007-08-02 | Novartis Ag | Verwendung von beschleunigten lymphozyten zielansteuernden wirkstoffen zur herstellung eines medikaments für die behandlung der verzögertern transplantat-funktion |
| JP5161567B2 (ja) * | 2004-05-14 | 2013-03-13 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体活性を阻害することによる同種移植片の生存の延長 |
| PL1772145T3 (pl) * | 2004-07-16 | 2011-08-31 | Kyorin Seiyaku Kk | Sposób skutecznego stosowania leku i sposób dotyczący zapobiegania efektom ubocznym |
| CN102600472A (zh) * | 2004-11-29 | 2012-07-25 | 诺瓦提斯公司 | S1p受体激动剂的剂量方案 |
| US20080206240A1 (en) * | 2005-02-08 | 2008-08-28 | Shreeram Aradhye | Antilymphocyte Antibody Induction |
| AU2006247857B2 (en) * | 2005-05-11 | 2009-10-22 | Loma Linda University | Substances, compositions and methods for preventing and treating immune-mediated inflammatory disorders |
| US20090191218A1 (en) | 2005-05-11 | 2009-07-30 | Fengchun Li | DNA Vaccines And Methods For The Prevention Of Transplantation Rejection |
| CN101346346B (zh) * | 2005-12-15 | 2012-08-22 | 田边三菱制药株式会社 | 胺化合物及其医药用途 |
| WO2007103134A2 (en) * | 2006-03-02 | 2007-09-13 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| CA2663026C (en) * | 2006-09-28 | 2013-04-16 | Loma Linda University | Apoptotic cell-mediated transfection of mammalian cells with interfering rna |
| TW200946105A (en) | 2008-02-07 | 2009-11-16 | Kyorin Seiyaku Kk | Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient |
| ES2965333T3 (es) * | 2008-03-12 | 2024-04-12 | Univ Loma Linda | Vacunas de ADN y procedimientos de prevención de rechazo tras un trasplante |
| HRP20170246T4 (hr) | 2008-03-17 | 2020-02-07 | Actelion Pharmaceuticals Ltd. | Režim doziranja za selektivni agonist s1p1-receptora |
| BRPI0921533A2 (pt) * | 2008-11-11 | 2016-01-12 | Novartis Ag | composto orgânicos |
| MX2011004962A (es) * | 2008-11-11 | 2011-05-30 | Novartis Ag | Formas cristalinas de hcl de fingolimod. |
| BRPI1016004A2 (pt) * | 2009-06-30 | 2016-04-26 | Lifescan Inc | métodos para testar analitos e dispositivo para calcular a terapia de insulina basal. |
| EP2449493A2 (en) * | 2009-06-30 | 2012-05-09 | Lifescan Scotland Limited | Systems for diabetes management and methods |
| BR112012007134A2 (pt) * | 2009-09-29 | 2016-08-23 | Lifescan Scotland Ltd | dispositivo e método de teste de analito para controle de diabetes |
| WO2011106029A1 (en) * | 2010-02-25 | 2011-09-01 | Lifescan Scotland Limited | Analyte testing method and system with high and low blood glucose trends notification |
| DK2758074T3 (da) | 2011-09-23 | 2020-07-27 | Univ Loma Linda | Bakteriestammer der udtrykker methylasegener og anvendelser deraf |
| US11680273B2 (en) | 2011-09-23 | 2023-06-20 | Loma Linda University | Treatment of autoimmune diseases |
| CN114306643A (zh) * | 2021-11-30 | 2022-04-12 | 中国科学院昆明动物研究所 | 一种恒河猴免疫抑制模型的构建方法及在car-t细胞植活上的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2579602B2 (ja) * | 1992-10-21 | 1997-02-05 | 吉富製薬株式会社 | ２−アミノ−１，３−プロパンジオール化合物および免疫抑制剤 |
| US5679546A (en) * | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
| EP0750458B1 (en) * | 1994-03-03 | 2003-08-27 | Alexion Pharmaceuticals, Inc. | Terminal complement inhibitor fusion genes and proteins |
| GB9624038D0 (en) * | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| DE60213766T2 (de) * | 2001-02-22 | 2007-08-02 | Novartis Ag | Verwendung von beschleunigten lymphozyten zielansteuernden wirkstoffen zur herstellung eines medikaments für die behandlung der verzögertern transplantat-funktion |
-
2002
- 2002-06-07 RU RU2003136730/15A patent/RU2003136730A/ru not_active Application Discontinuation
- 2002-06-07 BR BR0209319-7A patent/BR0209319A/pt not_active IP Right Cessation
- 2002-06-07 DE DE60231522T patent/DE60231522D1/de not_active Expired - Lifetime
- 2002-06-07 AT AT02754637T patent/ATE424893T1/de active
- 2002-06-07 JP JP2003502981A patent/JP4476623B2/ja not_active Expired - Fee Related
- 2002-06-07 US US10/164,755 patent/US20030003099A1/en not_active Abandoned
- 2002-06-07 PT PT02754637T patent/PT1429845E/pt unknown
- 2002-06-07 IL IL15838402A patent/IL158384A0/xx unknown
- 2002-06-07 WO PCT/EP2002/006278 patent/WO2002100148A2/en not_active Ceased
- 2002-06-07 NZ NZ529044A patent/NZ529044A/en unknown
- 2002-06-07 CA CA002445605A patent/CA2445605A1/en not_active Abandoned
- 2002-06-07 AU AU2002320828A patent/AU2002320828B2/en not_active Ceased
- 2002-06-07 PL PL02364359A patent/PL364359A1/xx not_active Application Discontinuation
- 2002-06-07 EP EP02754637A patent/EP1429845B1/en not_active Expired - Lifetime
- 2002-06-07 CN CNA028098498A patent/CN1524002A/zh active Pending
- 2002-06-07 ES ES02754637T patent/ES2322442T3/es not_active Expired - Lifetime
-
2003
- 2003-10-09 ZA ZA200307893A patent/ZA200307893B/en unknown
- 2003-12-05 NO NO20035434A patent/NO20035434D0/no not_active Application Discontinuation
-
2006
- 2006-03-09 US US11/372,383 patent/US20060153842A1/en not_active Abandoned
-
2008
- 2008-04-22 US US12/107,726 patent/US20080199465A1/en not_active Abandoned
-
2011
- 2011-06-06 US US13/154,106 patent/US20110236382A1/en not_active Abandoned
-
2013
- 2013-12-05 US US14/098,179 patent/US20140093502A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200307893B (en) | 2004-09-06 |
| JP2004534788A (ja) | 2004-11-18 |
| US20080199465A1 (en) | 2008-08-21 |
| CA2445605A1 (en) | 2002-12-19 |
| PL364359A1 (en) | 2004-12-13 |
| CN1524002A (zh) | 2004-08-25 |
| US20030003099A1 (en) | 2003-01-02 |
| BR0209319A (pt) | 2004-07-20 |
| JP4476623B2 (ja) | 2010-06-09 |
| WO2002100148A3 (en) | 2004-04-22 |
| RU2003136730A (ru) | 2005-05-20 |
| DE60231522D1 (de) | 2009-04-23 |
| US20060153842A1 (en) | 2006-07-13 |
| EP1429845A2 (en) | 2004-06-23 |
| US20110236382A1 (en) | 2011-09-29 |
| AU2002320828B2 (en) | 2006-02-02 |
| NZ529044A (en) | 2008-03-28 |
| NO20035434D0 (no) | 2003-12-05 |
| ATE424893T1 (de) | 2009-03-15 |
| ES2322442T3 (es) | 2009-06-22 |
| PT1429845E (pt) | 2009-06-15 |
| WO2002100148A2 (en) | 2002-12-19 |
| EP1429845B1 (en) | 2009-03-11 |
| US20140093502A1 (en) | 2014-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL158384A0 (en) | Treatment or prophylaxis of insulin producing cell graft rejection | |
| DE69713151D1 (de) | Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung | |
| NO954996L (no) | Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS | |
| PT1284140E (pt) | Utilização de ritonavir (abt-538) para melhorar a farmacocinética de fármacos metabolizados pelo citocromo p450 num método de tratamento da sida | |
| UA41995C2 (uk) | Лікарська форма азитроміцину з контрольованим вивільненням ( варіанти ), спосіб її введення, спосіб її виготовлення і спосіб лікування інфекційних захворювань ссавців з її використанням ( варіанти ) | |
| EA200200392A1 (ru) | Способ получения экстракта из растения рода trichocaulon или рода hoodia, экстракт, порошковый материал и композиция на его основе и их применение для производства медикамента для лечения, профилактики или преодоления ожирения и/или подавления аппетита | |
| AU2002236765A1 (en) | Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent | |
| NZ514574A (en) | Novel method of treatment | |
| GEP20002013B (en) | Therapeutical Means | |
| NO993520L (no) | Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon | |
| AU2855399A (en) | Vascularization inhibitors | |
| ZA967880B (en) | Compositions and methods for inhibition of the patho-physiologic actions in mammals in tumor necrosis facto-alpha | |
| IS5082A (is) | Pýrróló[3,4-D]pýrimídínon-afleiður og notkun þeirra sem lyfja | |
| CA2043440A1 (en) | Method of treating impotence | |
| MY111260A (en) | Pharmaceutical composition for the treatment of nicotine dependence | |
| PT921787E (pt) | Regime de administracao de inibidores de atpase de h',k' | |
| WO1998058669A3 (en) | Cd154 blockade therapy for pancreatic islet tissue transplantation | |
| WO2001078653A3 (en) | Graft rejection inhibition with ccr2 inhibitors | |
| NZ330944A (en) | Peptide derivatives | |
| EP0663835A1 (en) | USE OF PARATHORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES FOR THE TREATMENT OF PREGNANCY PROBLEMS. | |
| MY126450A (en) | Crystalline efavirenz | |
| MXPA02006511A (es) | Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido. | |
| IT1294931B1 (it) | Derivati della 2-amminotetralina procedimento per la loro preparazione e composizioni farmaceutiche che li contengono, attive nella | |
| TR200401810T4 (tr) | Kısırlık tedavisinde fsh'ın kullanılması | |
| UA66932C2 (en) | Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine |